175358-02-8

Basic information

• Product Name: 4,6-Dichloropyrido[3,2-d]pyrimidine
• Synonyms: 4,6-Dichloropyrido[3,2-d]pyrimidine
• CAS NO: 175358-02-8
• Molecular Formula: C₇H₃Cl₂N₃
• Molecular Weight: 200.028
• Mol File: 175358-02-8.mol

Chemical Properties

• Boiling Point: 314.616 °C at 760 mmHg
• Flash Point: 173.301 °C
• Appearance: /
• Density: 1.573
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.682
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.89±0.30(Predicted)
• CAS DataBase Reference: 4,6-Dichloropyrido[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloropyrido[3,2-d]pyrimidine(175358-02-8)
• EPA Substance Registry System: 4,6-Dichloropyrido[3,2-d]pyrimidine(175358-02-8)

Safety Data

• Hazardous Substances Data: 175358-02-8(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
4,6-Dichloropyrido[3,2-d]pyrimidine is used as a research compound for studying its chemical properties and reactivity. The exploration of its interactions with other compounds could lead to the discovery of new applications in the chemical industry.
Used in Pharmaceutical Development:
Although its uses are not well-defined, 4,6-Dichloropyrido[3,2-d]pyrimidine could potentially be used as a building block in the development of new pharmaceuticals. Its unique structure may offer opportunities for the creation of novel drug candidates, pending further research and development.
Used in Material Science:
In the field of material science, 4,6-Dichloropyrido[3,2-d]pyrimidine could be investigated for its potential to contribute to the development of new materials with specific properties, such as improved conductivity or stability, based on its chemical structure and reactivity.
Used in Dye and Pigment Production:
Given its aromatic nature, 4,6-Dichloropyrido[3,2-d]pyrimidine might be explored for its potential use in the production of dyes and pigments, where its chemical structure could impart unique color properties or stability to the final products.

InChI:InChI=1/C7H3Cl2N3/c8-5-2-1-4-6(12-5)7(9)11-3-10-4/h1-3H

Upstream product

• 866807-27-4 3-amino-6-chloro-pyridine-2-carboxylic acid 
• 37538-67-3 pyrido[3,2-d]-pyrimidin-4(3H)-one 
• 2402-78-0 2,6-dichloropyridine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 1242446-83-8 4-chloropyrido[3,2-d]pyrimidin-6-ol 
• 171178-33-9 6-chloropyrido[3,2-d]pyrimidin-4(1H)-one 
• 171178-21-5 6-chloro-3-nitropyridine-2-carboxamide 
• 175358-01-7 3-amino-6-chloro-pyridine-2-carboxylic acid amide 
• 93683-65-9 6-chloro-3-nitropicolinonitrile 
• 171178-33-9 6-chloropyrido<3,2-d>pyrimidin-4(3H)-one 

Downstream Products

• 855995-88-9 {2-[(allyl-methyl-amino)-methyl]-5-chloro-4-fluoro-phenyl}-(6-chloro-pyrido [3,2-d] pyrimidin-4-yl)-amine 
• 1242446-26-9 6-chloro-4-(3-(trifluoromethyl)phenyl)pyrido[3,2-d]pyrimidine 
• 1400668-23-6 6-chloro-N-(4-(trifluoromethoxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine 
• 1400668-15-6 6-chloro-4-(cyclohexylthio)pyrido[3,2-d]pyrimidine 
• 1499166-63-0 6-chloropyrido[3,2-d]pyrimidin-4-amine 

Relevant articles and documents

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

Optimization of 4,6-Disubstituted Pyrido[3,2-d]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth

Mitogen-activated protein kinase-interacting kinases (MNKs) and provirus integration in maloney murine leukemia virus kinases (PIMs) are downstream enzymes of cell proliferation signaling pathways associated with the resistance of tyrosine kinase inhibitors. MNKs and PIMs have complementary effects to regulate cap-dependent translation of oncoproteins. Dual inhibitors of MNKs and PIMs have not been developed. We developed a novel 4,6-disubstituted pyrido[3,2-d]pyrimidine compound 21o with selective inhibition of MNKs and PIMs. The IC50’s of 21o to inhibit MNK1 and MNK2 are 1 and 7 nM and those to inhibit PIM1, PIM2, and PIM3 are 43, 232, and 774 nM, respectively. 21o inhibits the growth of myeloid leukemia K562 and MOLM-13 cells with GI50’s of 2.1 and 1.2 μM, respectively. 21o decreases the levels ofp-eIF4E andp-4EBP1, the downstream products of MNKs and PIMs, as well as cap-dependent proteins c-myc, cyclin D1, and Mcl-1. 21o inhibits the growth of MOLM-13 cell xenografts without causing evident toxicity. 21o represents an innovative dual MNK/PIM inhibitor with a good pharmacokinetic profile.

Design, synthesis and bioactivity evaluation of 4,6-disubstituted pyrido[3,2-d]pyrimidine derivatives as mnk and HDAC inhibitors

Both HDACs and Mnks play important role in translating multiple oncogenic signaling pathways during oncogenesis. As HDAC and Mnk are highly expressed in a variety of tumors; thus simultaneous inhibit HDAC and Mnk can increase the inhibition of tumor cell proliferation and provide a new way of inhibiting tumor growth. Based on the previous work and the merge pharmacophore method; we designed and synthesized a series of 4,6-disubstituted pyrido[3,2-d]pyrimidine derivatives as HDAC and Mnk dual inhibitors. Among them; compound A12 displayed good HDAC and Mnk inhibitory activity. In vitro antiproliferative assay; compound A12 exhibited the best antiproliferative activity against human prostate cancer PC-3 cells. Docking study revealed that the pyrido[3,2-d]pyrimidine framework and hydroxamic acid motif of compound A12 were essential for maintaining the activity of HDAC and Mnk. These result indicated that A12 was a potent Mnk /HDAC inhibitor and will be further researched.

4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound as well as preparation and application thereof

The invention belongs to the technical field of medicines. The invention relates to the field of pharmaceutical chemistry, in particular to a 4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound and pharmaceutically acceptable salt thereof, a preparation method of the compound, a pharmaceutical composition taking the compound as an active ingredient, and application of the compound in preparation of an MNK inhibitor and drugs for treating and/or preventing various cancers and/or metabolic diseases. The present invention relates to compounds represented by formulas I, II, III or IV, and pharmaceutically acceptable salts, hydrates, solvates and metabolites thereof, wherein the variables are described in the claims and the description.

HETEROCYCLIC INHIBITORS OF TYROSINE KINASE

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.

Discovery of selective 4-amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization

Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) is a serine/threonine kinase implicated in the regulation of many biological processes. A fragment-based lead discovery approach was used to generate potent and selective MAP4K4 inhibitors. The fragment hit pursued in this article had excellent ligand efficiency (LE), an important attribute for subsequent successful optimization into drug-like lead compounds. The optimization efforts eventually led us to focus on the pyridopyrimidine series, from which 6-(2-fluoropyridin-4-yl)pyrido[3,2-d]pyrimidin-4-amine (29) was identified. This compound had low nanomolar potency, excellent kinase selectivity, and good in vivo exposure, and demonstrated in vivo pharmacodynamic effects in a human tumor xenograft model.

NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF

The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.